Latest News & Features
Generics
Final award follows and incorporates the August 2022 decision by the arbitrator denying all claims levied at the Japanese company | Dispute involves antibody drug conjugate technology. 30 November 2023
Europe
UPC judge, EPO director and Regeneron counsel shed light on the court’s dynamics at London event | Life sciences sector emerging as a major player in the court | Quality of rulings and tight timeframes blamed for lack of appeals. 28 November 2023
Big Pharma
Rival drugmakers have dropped lawsuit following invalidation of Teva patents in September | Move comes after judge overturned jury verdict handing $176.5m to Teva. 28 November 2023
Europe
Is the court’s public access rule unfit for purpose? Lawyers at Mathys & Squire are arguing for pleadings and evidence to be automatically made available on request, finds Muireann Bolger. 28 November 2023
Americas
An ambiguous decision by the Supreme Court has paved the way for frivolous petitions for compensation and clarity is needed, say Daniel Sanchez and Karla Olvera of Olivares. 28 November 2023
article
With his ‘extensive’ scientific background and links to Nobel-Prize-winning inventions, Christopher North brings a wealth of experience and knowledge to Panitch Schwarze’s patent team. 28 November 2023
Europe
LSPN Europe delved into the challenges of aligning researchers goals with IP and legal frameworks | Disclosure forms, valuing relationships, incentivising researchers and education. 23 November 2023
Big Pharma
Judge encourages lawyers and public to make their voices heard over transparency concerns | Awkward access to public hearings ‘causing problems’ says Regeneron counsel | Plea for public virtual hearings as judge notes that requests have been ‘coming in by the dozen’ | Panellists discuss at LSPN Europe. 23 November 2023
Big Pharma
The European Patent Office hands a win to BioNTech and Pfizer in coronavirus vaccine dispute | US biotech plans to appeal decision affecting mRNA patent. 23 November 2023
Biotechnology
Recent clashes over patents covering modified guide RNAs have exposed different approaches from the US and Europe—and new complications for the field, says Claire Irvine of HGF. 21 November 2023